Jason Hope wants AGE to Change how People Age

Jason Hope is a futurist. He is also a well-known technology guru. He has a knack for predicting the future use of science in its relation to business and society. As a matter of fact, he wholeheartedly believes that the Internet of Things is going to be the next technological process that will impact the future economy.

While Mr. Hope really enjoys technology, he also is fond of medical research and what it can do to improve the quality of life. Cellular regeneration is one area of medical research that Mr. Jason Hope is very excited about. The reason why is that he believes that cellular regeneration is the key to slowing down the aging process.

No one can completely stop a person from growing older. Hope does not expect that. However, he does believe that people should grow older at a much slower pace. He is a firm believer in this process. He also realizes that some research organizations have the ability to perform this process. The Strategies for Engineered Negligible Senescence Research Foundation or SENS is a leading organization that is carrying out this type of work.

SENS performs a series of research related to AGEs or advanced glycation end-products. Ages are compounds that are generated within the human body through chemical reactions. They are a byproduct of these reactions. They usually form when certain amino acids connect with sugars. SENS researchers realize that AGEs are linked to many of the harmful diseases that people are prone to get once they start to grow older.

Diseases related to the heart, liver and kidneys are influenced by AGEs compounds. Even conditions such as cancer is also impacted by the amount of AGEs products found within the body. Hope wants SENS researchers to figure out how to eliminate or at least slow down these harmful materials. He knows that young people typically do not struggle with AGEs products. So, he believes that SENS researchers will find a way to mitigate this substance.

Hope has given millions for this research project. He wants this organization to find success. Hope knows that if a solution can be found, it will revolutionize how people live their lives. Hope firmly believes that this medical research is going to help define how humanity will exist in the future.

Mikhail Blagosklonny – the undisputed Oncologist

Mr. Mikhail Blagosklonny is an undisputed scientist and a professor of oncology who currently works at RPCI (Roswell Park Cancer Institute). He earned both his master degree in internal medicine and Ph.D. in cardiology and experimental medicine from First Pavlov State Medical University. Before joining Roswell Park Cancer Institute, Mikhail was an associate professor at the New York Medical College. Furthermore, Mikhail worked as a scientist at the Ordway Research Institute, where most of his research were focusing on cancer treatment, anti-aging drugs, aging mechanism, and cancer therapies. Perhaps, Blagosklonny is a passionate advocate of the cancer drug known as Rapamycin. He even developed a hypothesis on the role of TOR signaling in aging and cancer treatment. According to the hypothesis, Rapamycin drug can prolong the life of a human being.

Mikhail Blagosklonny serves as a chief editor to several publications such as Cell Cycle and Oncotarget. He also works as an associate editor of the editorial board of Cancer Therapy and Biology. He understands that it is not a miracle to have a society that is free from aging and cancer effects. Because of this reason, Mikhail has dedicated most of his time in conducting more research in oncology study. In addition to his hypothesis, Blagosklonny zeroes in cellular biology, molecular biology, tumor suppressors, clinical investigation, ontogenesis, and anti-cancer therapeutics. Also, Mikhail has made a lot of contributions to the science journals. He believes that through journals, people can be aware of the things that are happening in their life. Mr. Mikhail Blagosklonny has written more than 300 articles. Most of his publications are about cell cyclotherapy, aging hyperfunction, and chemotherapeutic engineering.

Visit ResearchGate.Net to know more about Mikhail’s latest work.